TPO, but not soluble-IL-6 receptor, levels increase after anagrelide treatment of thrombocythemia in chronic myeloproliferative disorders

Anagrelide is often used in the treatment of thrombocythemia in myeloproliferative disease (MPD), but information concerning effects of treatment on cytokines involved in regulation of blood platelet levels is limited. Here, we investigated serum levels of thrombopoietin (TPO) and soluble IL-6 recep...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Palmblad, Jan, Björkholm, Magnus, Kutti, Jack, Lärfars, Gerd, Löfvenberg, Eva, Markevärn, Berit, Merup, Mats, Mauritzson, Nils, Westin, Jan, Samuelsson, Jan, Birgegård, Gunnar
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Ivyspring International Publisher 2008
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2293642/
https://ncbi.nlm.nih.gov/pubmed/18414650
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak